Shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) have been given an average recommendation of “Buy” by the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $16.14.
A number of equities analysts recently commented on the stock. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $15.00 price objective on shares of Inozyme Pharma in a report on Monday. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Tuesday, August 6th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $17.00 price objective (up previously from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th.
Get Our Latest Stock Analysis on Inozyme Pharma
Institutional Investors Weigh In On Inozyme Pharma
Inozyme Pharma Price Performance
INZY opened at $5.02 on Wednesday. The stock has a market capitalization of $310.52 million, a P/E ratio of -3.66 and a beta of 1.52. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80. The stock has a 50-day moving average price of $5.25 and a 200-day moving average price of $5.12.
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Equities analysts predict that Inozyme Pharma will post -1.68 earnings per share for the current fiscal year.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Read More
- Five stocks we like better than Inozyme Pharma
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Investors Need to Know About Upcoming IPOs
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Pros And Cons Of Monthly Dividend Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.